Surrogate endpoints in clinical trials of chronic kidney disease progression: Moving from single to multiple risk marker response scores

Current Opinion in Nephrology and Hypertension

Volumn 24, Issue 6, 2015, Pages 492-497

  Schievink, Bauke ^a   Mol, Peter G M ^a,b   Heerspinka, Hiddo J Lambers ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b MEDICINES EVALUATION BOARD   (Netherlands)

Author keywords

biomarkers, end stage renal disease, glomerular filtration rate, nephrology, surrogate endpoints

Indexed keywords

ALBUMIN; ATRASENTAN; BIOLOGICAL MARKER; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IRBESARTAN; LOSARTAN; PENTOXIFYLLINE; XANTHINE DERIVATIVE;

ALBUMINURIA; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL (TOPIC); CREATININE BLOOD LEVEL; DIABETIC PATIENT; DISEASE COURSE; DRUG EFFICACY; END STAGE RENAL DISEASE; GLOMERULUS FILTRATION RATE; HUMAN; NEPHROLOGY; OUTCOME ASSESSMENT; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; RENAL PROTECTION; REVIEW; ANIMAL; KIDNEY; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; RENAL INSUFFICIENCY, CHRONIC;

ALBUMINURIA; ANIMALS; BIOMARKERS; DISEASE PROGRESSION; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY; RENAL INSUFFICIENCY, CHRONIC;

EID: 84944076978     PISSN: 10624821     EISSN: 14736543     Source Type: Journal    
DOI: 10.1097/MNH.0000000000000159     Document Type: Review

References (45)

1. Liyanage T, Ninomiya T, Jha V, et al. Worldwide access to treatment for end-stage kidney disease: a systematic review. Lancet 2015; 385:1975-1982.
2. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345:861-869.
3. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345:851-860.
4. Parving H, Brenner BM, McMurray JJV, et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 2012; 367:2204-2213.
5. Palmer SC, Sciancalepore M, Strippoli GFM. Trial quality in nephrology: how are we measuring up? Am J Kidney Dis 2011; 58:335-337.
6. DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J Health Econ 2003; 22:151-185.
7. DiMasi JA, Feldman L, Seckler A, Wilson A. Trends in risks associated with new drug development: success rates for investigational drugs. Clin Pharmacol Ther 2010; 87:272-277.
8. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001; 69:89-95.
9. Levey AS, Inker LA, Matsushita K, et al. GFR decline as an end point for clinical trials in CKD: a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration. Am J Kidney Dis 2015; 64:821-835.
10. Inker LA, Lambers Heerspink HJ, Mondal H, et al. GFR decline as an alternative end point to kidney failure in clinical trials: a meta-analysis of treatment effects from 37 randomized trials. Am J Kidney Dis 2015; 64:848-859.
11. Coresh J, Turin T, Matsushita K, et al. Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality. JAMA 2014; 311:2518-2531.
12. Lambers Heerspink HJ, Weldegiorgis M, Inker LA, et al. eGFR decline as a surrogate end point for kidney failure: a post hoc analysis from the Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan (RENAAL] Study and Irbesartan Diabetic Nephropathy Trial (IDNT). Am J Kidney Dis 2014; 63:244-250.
13. Sontrop JM, Weir MA, Garg AX. Surrogate outcomes for ESRD Risk: the case for a 30% reduction in estimated GFR over 2 years. Am J Kidney Dis 2014; 64:845-847.
14. Lambers Heerspink HJ, Tighiouart H, Sang Y, et al. GFR decline and subsequent risk of established kidney outcomes: a meta-analysis of 37 randomized controlled trials. Am J Kidney Dis 2015; 64:860-866.
15. Greene T, Teng C, Inker LA, et al. Utility and validity of estimated GFR-based surrogate time-to-event end points in CKD: a simulation study. Am J Kidney Dis 2015; 64:867-879.
16. European Medicines Agency. Draft guideline on the clinical investigation of medicinal products to prevent development/slow progression of chronic renal insufficiency. EMA/CHMP/355988/2014. 2014; Available at: http://www.ema.europa.eu/ema/doc-index.jsp?curl=pages/includes/document/document-detail.jsp?webContentId=WC500169469&murl=menus/document- library/document-library.jsp&mid=0b01ac058009a3dc. [Accessed 16 April 2015]
17. Holtkamp FA, de Zeeuw D, Thomas MC, et al. An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function. Kidney Int 2011; 80:282-287.
18. Weir MR. Acute fall in glomerular filtration rate with renin-angiotensin system inhibition: a biomeasure oftherapeutic success. Kidney Int 2011; 80:235-237.
19. Myers GL, Miller WG, Coresh J, et al. Recommendations for improving serum creatinine measurement: a report from the Laboratory Working Group of the National Kidney Disease Education Program. Clin Chem 2006; 52:5-18.
20. Drion I, Cobbaert C, Groenier K, et al. Clinical evaluation of analytical variations in serum creatinine measurements: why laboratories should abandon Jaffe techniques. BMC Nephrol 2012; 13:133.
21. Gaspari F, Ruggenenti P, Porrini E, et al. The GFR and GFR decline cannot be accurately estimated in type 2 diabetics. Kidney Int 2013; 84:164-173.
22. Greene T. A model for a proportional treatment effect on disease progression. Biometrics 2001; 57:354-360.
23. Roscioni SS, Lambers Heerspink HJ, de Zeeuw D. Microalbuminuria: target for renoprotective therapy PRO. Kidney Int 2014; 86:40-49.
24. Parving H, Persson F, Rossing P. Microalbuminuria: a parameter that has changed diabetes care. Diabetes Res Clin Pract 2015; 107:1-8.
25. Abbate M, Zoja C, Remuzzi G. How does proteinuria cause progressive renal damage? J Am Soc Nephrol 2006; 17:2974-2984.
26. de Zeeuw D, Remuzzi G, Parving H, et al. Proteinuria, a target for renoprotec-tion in patients with type 2 diabetic nephropathy: Lessons from RENAAL. Kidney Int 2004; 65:2309-2320.
27. Hellemons ME, Persson F, Bakker SJL, et al. Initial angiotensin receptor blockade-induced decrease in albuminuria is associated with long-term renal outcome in type 2 diabetic patients with microalbuminuria: a post hoc analysis of the IRMA-2 trial. Diabetes Care 2011; 34:2078-2083.
28. Atkins RC, Briganti EM, Lewis JB, et al. Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy. Am J Kidney Dis 2005; 45:281-287.
29. Navarro-González JF, Mora-Fernández C, Muros de Fuentes M, et al. Effect of pentoxifylline on renal function and urinary albumin excretion in patients with diabetic kidney disease: The PREDIAN Trial. J Am Soc Nephrol 2015; 26:220-229.
30. de Zeeuw D, Anzalone DA, Cain VA, et al. Renal effects of atorvastatin and rosuvastatin in patients with diabetes who have progressive renal disease (PLANET I): a randomised clinical trial. Lancet Diabetes Endocrinol 2015; 3:181-190.
31. Witte EC, Lambers Heerspink HJ, de Zeeuw D, et al. First morning voids are more reliable than spot urine samples to assess microalbuminuria. J Am Soc Nephrol 2009; 20:436-443.
32. Kröpelin TF, de Zeeuw D, Andress DL, et al. Number and frequency of albuminuria measurements in clinical trials in diabetic nephropathy. Clin J Am Soc Nephrol 2015; 10:410-416.
33. Hou FF, Xie D, Zhang X, et al. Renoprotection of Optimal Antiproteinuric Doses (ROAD) Study: a randomized controlled study of benazepril and losartan in chronic renal insufficiency. J Am Soc Nephrol 2007; 18:1889-1898.
34. Miao Y, Dobre D, Lambers Heerspink HJ, et al. Increased serum potassium affects renal outcomes: a post hoc analysis of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. Diabe-tologia 2011; 54:44-50.
35. Heerspink HJL, Gao P, Zeeuw D, et al. The effect of ramipril and telmisartan on serum potassium and its association with cardiovascular and renal events: Results from the ONTARGET trial. Eur J Prev Cardiol 2014; 21:299-309.
36. Mann JFE, Green D, Jamerson K, et al. Avosentan for overt diabetic nephro-pathy. J Am Soc Nephrol 2010; 21:527-535.
37. The ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358:1547-1559.
38. Fried LF, Emanuele N, Zhang JH, et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med 2013; 369:1892-1903.
39. James WP, Caterson ID, Coutinho W, et al. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med 2010; 363:905-917.
40. Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007; 357:2109-2122.
41. Heerspink HJL, Grobbee DE, de Zeeuw D. A novel approach for establishing cardiovascular drug efficacy. Nat Rev Drug Discov 2014; 13:942.
42. Smink PA, Miao Y, Eijkemans MJC, et al. The importance of short-term off-target effects in estimating the long-term renal and cardiovascular protection of angiotensin receptor blockers. Clin Pharmacol Ther 2014; 95:208-215.
43. Schievink B, de Zeeuw D, Parving H, et al. The renal protective effect of angiotensin receptor blockers depends on intra-individual response variation in multiple risk markers. Br J Clin Pharmacol 2015; doi: 10.1111/bcp.12655. [Epub ahead of print]
44. Smink P, Hoekman J, Grobbee D, et al. A prediction of the renal and cardiovascular efficacy of aliskiren in ALTITUDE using short-term changes in multiple risk markers. Eur J Prev Cardiol 2014; 21:434-441.
45. Mullen W, Delles C, Mischak H. EuroKUP COST action. Urinary proteomics in the assessment of chronic kidney disease. Curr Opin Nephrol Hypertens 2011; 20:654-661.